Trial intelligence / Profile preview

Phase 3 long-term study of JTE-061 cream 1% in plaque psoriasis

jRCT2031210254Phase 3Completed

Sponsor
Japan Tobacco
Start
Sep 2021
Modality
Small Molecules
Countries
1
01

Overview

Phase 3, open-label, single-arm trial of tapinarof in plaque psoriasis, sponsored by Japan Tobacco. Primary endpoints: Safety (adverse events and adverse drug reactions), Safety (laboratory tests) and 1 more. Started Sep 2021; status: completed.

02

Drugs

tapinarof
03

Conditions

plaque psoriasis

Beyond the preview

Go deeper on jRCT2031210254.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on jRCT2031210254.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call